In Vitro and In Vivo Studies of Non-Platinum-Based Halogenated Compounds as Potent Antitumor Agents for Natural Targeted Chemotherapy of Cancers.

Based on a molecular-mechanism-based anticancer drug discovery program enabled by an innovative femtomedicine approach, we have found a previously unknown class of non-platinum-based halogenated molecules (called FMD compounds) as potent antitumor agents for effective treatment of cancers. Here, we present in vitro and in vivo studies of the compounds for targeted chemotherapy of cervical, breast, ovarian, and lung cancers. Our results show that these FMD agents led to DNA damage, cell cycle arrest in the S phase, and apoptosis in cancer cells.

[Progress on research and clinical application of interleukin-11 in treatment of leukemia--review].

Interleukin-11 (IL-11) is a multifunctional cytokine that directly acts on hematopoietic progenitors, macrophage, T cells, epithelial cells and hepatocytes, as well as promotes hematopoiesis, regulates immunity, protects mucosa and epithelium, and has the effect of anti-inflammatory. Preclinical and clinical studies have demonstrated that IL-11 effectively accelerates the recovery of peripheral blood platelets of acute leukemia patients after chemotherapy. In the hematopoietic stem cell transplantation, IL-11 prevents and treats the graft-versus-host disease leading to the effect of graft-versus-leukemia.